To compare disease-free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone.
Thank you for your interest, but this study is not currently enrolling.
North Carolina
Tracy Rose
Lineberger Comprehensive Cancer Center
Clinical or Medical
Interventional
Cancer (Kidney, Other Cancers)
Kidneys and Liver
Urinary and Bladder
25-0822
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
